KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Invested Capital: 2009-2025

Historic Invested Capital for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $6.1 billion.

  • Biomarin Pharmaceutical's Invested Capital rose 11.88% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 11.88%. This contributed to the annual value of $5.7 billion for FY2024, which is 3.90% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Invested Capital is $6.1 billion, which was up 0.49% from $6.0 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's Invested Capital's 5-year high stood at $6.1 billion during Q3 2025, with a 5-year trough of $4.2 billion in Q1 2021.
  • Its 3-year average for Invested Capital is $5.5 billion, with a median of $5.6 billion in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first dropped by 2.57% in 2021, then increased by 20.87% in 2024.
  • Biomarin Pharmaceutical's Invested Capital (Quarterly) stood at $4.3 billion in 2021, then climbed by 7.07% to $4.6 billion in 2022, then climbed by 17.89% to $5.4 billion in 2023, then grew by 3.90% to $5.7 billion in 2024, then rose by 11.88% to $6.1 billion in 2025.
  • Its last three reported values are $6.1 billion in Q3 2025, $6.0 billion for Q2 2025, and $5.8 billion during Q1 2025.